RAND reported Q1 2026 results today that crystallised the challenge facing this small Buffalo-based BDC: a portfolio in transition, nonaccruals weighing on income, and a widening gap between net asset value and market price.
Q1 adjusted EPS came in at $0.18, down sharply from $0.40 in the same period a year ago. Revenue fell to $1.24 million from $2.01 million. CEO Dan Penberthy described the quarter as a "transition period," pointing to the repayment of several higher-yielding debt investments during 2025 and the drag from two nonaccrual names — FSS and MRES — which pulled the annualised weighted average yield on debt investments down to 9.43% from 11.3% at year-end. The stock closed at $10.80, roughly 37% below NAV of $17.16 per share, a discount that reflects market scepticism about how quickly Rand can rebuild its income-producing portfolio base.
The lending market carries essentially no signal here. Availability is loose — ORTEX data shows the borrow pool is almost entirely untapped, with availability running at over 9,900% of short interest. Cost to borrow sits at 2.13%, and has drifted down roughly 5.5% over the past month. Short interest itself has collapsed: from a brief spike toward 2,700 shares in late March, borrowed shares fell to around 25 at the most recent read — statistically negligible for a company of any size. The ORTEX short score of 26.4 out of 100 confirms there is nothing remotely crowded on the short side. This is not a stock under siege from short sellers; it is one that the market simply appears to be pricing at a deep discount and then leaving alone.
The more substantive tension is on the fundamental side. Rand's portfolio grew to $51.5 million in fair value across 20 companies at March 31, up from $48.5 million at year-end, and new deployment totalled $5.1 million in the quarter — including a $4 million investment in AME Holdco. The company also monetised its remaining equity in Cyber (the RAC Group) for $1.3 million in proceeds and a realised gain of $1.1 million, a clean example of the capital recycling model working as intended. But the pipeline of nonaccruals — FSS and MRES are both in workout — is keeping investors cautious. New debt investments are being priced at 13–14%, suggesting the underlying spread on fresh origination is healthy; the issue is volume, not rate.
The dividend is a meaningful anchor. Rand paid $0.29 per share in Q1 and has declared another $0.29 for Q2 2026. At the current share price, that annualises to roughly 10.7% — well above what the Q1 net investment income of $0.18 per share can cover on a standalone quarterly basis. Management has flagged that the gap between GAAP and RIC tax-basis accounting is providing flexibility for now, and balance sheet capacity is solid: over $20 million in available liquidity with only $500,000 drawn on the credit line. The earlier insider activity in the data — Independent Director Adam Gusky buying in September 2025 at prices between $14.55 and $15.00 — is stale and predates a share price that has since fallen materially, making it a datapoint about prior conviction rather than current signalling.
The earnings history shows two prior results events where the stock moved modestly on the day (+1.5% and +1.5%) before slipping over the following five days (-1.7% and -2.7%). Today's print follows that pattern with a flat close, but the month-to-date move of nearly -8% had already done significant damage ahead of the report. The key question going forward is the pace of portfolio rebuilding: Penberthy's emphasis on "capital recycling" and a debt-oriented mix suggest the dividend is the primary mechanism for retaining investor interest while income recovers, and the $17.16 NAV remains the longer-term yardstick against which that effort will be measured.
See the live data behind this article on ORTEX.
Open RAND on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
